verapamil has been researched along with Tremor in 2 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Tremor: Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.
Excerpt | Relevance | Reference |
---|---|---|
"Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 7.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
"Acute effects of two calcium blockers, nifedipine and verapamil, were investigated on the tremor activity of 8 patients with essential tremor and compared with those of propranolol and placebo." | 5.06 | Calcium channel blockers and essential tremor. ( Dalkara, T; Onur, R; Topaktas, S, 1987) |
"Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 3.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gomez-Mancilla, B | 1 |
Latulippe, JF | 1 |
Boucher, R | 1 |
Bédard, PJ | 1 |
Topaktas, S | 1 |
Onur, R | 1 |
Dalkara, T | 1 |
1 trial available for verapamil and Tremor
Article | Year |
---|---|
Calcium channel blockers and essential tremor.
Topics: Adult; Blood Pressure; Female; Humans; Male; Middle Aged; Nifedipine; Propranolol; Tremor; Verapamil | 1987 |
1 other study available for verapamil and Tremor
Article | Year |
---|---|
Effect of ethosuximide on rest tremor in the MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diltiazem; Dopamine Agents; Dose-Response Rel | 1992 |